CANCELLED: 19th ESO-ESMO Masterclass in Clinical Oncology
Not eligible for ESCO credits
21.03.2020 - 26.03.2020
Seva (Barcelona area), Spain
MASTERCLASS
Important information
On behalf of ESO and ESMO we would like to inform you that due to the ongoing Coronavirus (COVID-19) crisis we have made the difficult decision to cancel the 19th ESO-ESMO Masterclass in Clinical Oncology programmed for 21st to 26th March in Seva (Barcelona area), Spain.
We deeply regret having to take this decision but we feel that in the current climate we all need to do our part in trying to limit the diffusion of the virus as much as possible and this was the only decision possible considering your role in society as medical staff.
We have discussed the possibility of postponing the event to later this year, but due to other already planned activities we have decided that postponing is not a viable solution.
We apologize for any inconvenience caused but we think you’ll all agree that this solution was unavoidable.
Description
Chairs: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Advisors: F. Lordick, DE - R. Popescu, CH
AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam.
The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, gastro-intestinal, lung, genito-urinary, gynaecological, head and neck cancers.
Spotlight sessions will facilitate compact update on mentorship, cancer of unknown primary, molecular tumour board (including liquid biopsy), cultural diversity, basic public speaking, immuno-oncology, melanoma, nutrition, neuroendocrine tumours, burn-out syndrome, early integration in oncology and palliative care, fertility presentation and pregnancy in cancer patients, brain tumours, mind body medicine.
TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairmen and the faculty. Informal discussion will be facilitated during the lunches and the aperitifs with the experts.
All participants will reside at the course venue and participation is compulsory throughout the course.
The Masterclass will be entirely in English and fluency in English is necessary for admission.
Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the communication skills sessions will be attended jointly.
THE MASTERCLASS IS
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.
In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”
• Download PDF document
Faculty
INVITED FACULTY
A. Aapro, Clinique de Genolier, CH
A. Arber, University of Surrey, Faculty of Health and Medical Sciences, Guildford, UK
J. Arends, Freiburg University Hospital, Freiburg, DE
S. Banerjee, The Royal Marsden NHS Trust Foundation, London, UK
G. Curigliano, European Institute of Oncology, Milan, IT
M. De Santis, Charité University Hospital, Berlin, DE
A. Dietz, University Hospital Leipzig, Leipzig, DE
A. Eggermont, Princess Máxima Center for Pediatric Oncology, Utrech, NL
A. Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, RO
K. Fizazi, Institut Gustave Roussy, Villejuif (Paris), FR
T. Gagliardi, Royal Marsden Hospital, London, UK
W. Gatzemeier, Humanitas Cancer Center, Rozzano, IT
D. Hart, Cameron Communications, London, UK
S. Hillinger, University Hospital, Zurich, CH
A. Hoy, Consultant in Palliative Medicine, Epson, UK
S. Joosse, University Medical Center Hamburg-Eppendorf, Hamburg, DE
N. Koppotsch, Charité University Hospital, Berlin, DE
A. Letsch, Universitätsklinikum Schleswig-Holstein, Kiel, DE
F. Lordick, University Hospital Leipzig, University Cancer Center, Leipzig, DE
F. Mc Donald, The Royal Marsden NHS Foundation Trust, London, UK
R. Orecchia, European Institute of Oncology, Milan, IT
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
N. Pavlidis, University Hospital of Ioannina, Ioannina, GR
F.A. Peccatori, European Institute of Oncology, Milan, IT
M. Pera, Universitat Autónoma de Barcelona, Barcelona, ES
R. Popescu, Hirslanden Klinik Aarau, Tumor Center, Aarau, CH
G. Pruneri, University of Milan – European Institute of Oncology, Milan, IT
M. Schumacher, Hirslanden Klinik Aarau, Aarau, CH
C. Sessa, Oncology Institute of Southern Switzerland, Bellinzona, CH
L. Sharp, Regional Cancer Centre, Stockholm, SE
R.A. Stahel, University Hospital, Zurich, CH
C. Toumpanakis, Royal Free Hospital, London, UK
E. Van Cutsem, University Hospital Leuven, Leuven, BE
R. Verity, King's College London, London, UK
J.B. Vermorken, Antwerp University Hospital, Edegem, BE
M. Weller, University Hospital Zurich, Zurich, CH
C. Witt, University Hospital Zurich and University of Zurich, Zurich, CH
I. Zapardiel, La Paz University Hospital, Madrid, ES
General information
ORGANISING SECRETARIAT
Alice Ciocchini
Ph: +39 02 85464529
Email: aciocchini@eso.net
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Fax: +39 02 85464545
Applications
Corinne Hall
Ph: +39 02 85464522
Email: chall@eso.net
ACCREDITATION
Application for CME recognition will be submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.
SOCIAL MEDIA
Follow updates, send questions and join in the discussions using #20MCO on Twitter and Facebook.
IMPORTANT DEADLINES |
||
Application deadline: | 01 December 2019 | |
---|---|---|
Save event date: | 21 March 2020 | |
Early registration by: | insert the date | |
Late registration by: | insert the date | |
Onsite registration from: | insert the date |
Application
IDEAL MASTERCLASS CANDIDATE
• Age between 30 and 40 years
• At least 2-3 years’ experience in medical oncology or clinical oncology
• Involvement in scientific activities
• Fluency in English
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and accommodation
THE APPLICATION DEADLINE HAS PASSED (1 DECEMBER 2019)
Programme
21 March
Participants' arrival, airport transfers, registration | ||
13:00 | Lunch |
|
14:00 | Focus on ESO, ESMO and EONS N. Pavlidis, GR - R. Stahel, CH - R. Verity, UK |
|
PARALLEL SESSIONS | ||
14:30 | Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK |
|
14:30 | Warm up + Case presentations by participants - 2 Groups R. Popescu, CH - R.A. Stahel, CH |
|
16:30 |
Coffee break |
|
17:00 | Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK |
|
17:00 |
Warm up + Case presentations by participants - 2 Groups F. Lordick, DE - N. Pavlidis, GR |
|
20:00 | Dinner |
22 March
8:15 | Clinical session Lung cancer Chair: R.A. Stahel, CH |
|
Systemic therapy for NSCLC without oncogenic driver mutations R.A. Stahel, CH Systemic therapy for NSCLC with oncogenic driver mutation R.A. Stahel, CH Radiotherapy in the treatment of NSCLC F. Mc Donald, UK Multimodality treatment of SCLC F. Mc Donald, UK General discussion |
||
11:00 | Coffee break | |
11:30 | Tumour board Lung cancer R.A. Stahel, CH - F. Mc Donald, UK - S. Hillinger, CH |
|
12:30 | Spotlight session Burnout syndrome S. Banerjee, UK |
|
13:00 | Lunch with the expert |
|
14:00 | Molecular Tumour Board (including Liquid Biopsy) S. Joosse, DE |
|
14:40 | Spotlight session Mentorship R.A. Stahel, CH |
|
15:10 | Spotlight session Cultural Diversity L. Sharp, SE |
|
15:40 | Spotlight session Basic public speaking D. Hart, UK |
|
16:25 | Case presentations by participants (4 groups) F. Lordick, DE - N. Pavlidis, GR - R. Popescu, CH - R.A. Stahel, CH |
|
19:30 | Dinner |
|
21:00 | Games night |
23 March
8:15 |
Clinical session Gastro-intestinal tumours Chair: E. van Cutsem, BE |
|
Systemic treatment in early and advanced gastric cancer F. Lordick, DE Principles of oncological surgery - the example of esophago-gastric surgery M. Pera, ES Pancreatic cancer R. Popescu, CH Systemic treatment in adjuvant setting in colon cancer E. van Cutsem, BE |
||
10:15 | Coffee break |
|
Systemic treatment in advanced colon cancer E. van Cutsem, BE The role of surgery in stage IV gastrointestinal cancer M. Pera, ES |
||
General discussion | ||
12:00 | Tumour board Gastro-intestinal tumours F. Lordick, DE - R. Popescu, CH - E. van Cutsem, BE - M. Pera, ES |
|
13:00 | Lunch with the expert |
|
14:00 | Spotlight session Case presentations (3 cases) on Immunoncology G. Curigliano, IT |
|
14:45 | Spotlight session Immunoncology G. Curigliano, IT |
|
15:40 | Spotlight session Melanoma A. Eggermont, NL |
|
16:30 | Coffee break |
|
17:00 | Spotlight session Nutrition J. Arends, DE |
|
17:30 | Spotlight session Cancer in Elderly patients M. Aapro, CH |
|
19:30 | |
Dinner |
24 March
8:15 | Clinical session Breast cancer (early and advanced) Chairs: O. Pagani, CH - A. Eniu, RO |
|
Radiology T. Gagliardi, UK Surgery W. Gatzemeier, IT Pathology G. Pruneri, IT Radiation therapy R. Orecchia, IT Systemic treatment O. Pagani, CH |
||
10:20 | Coffee break |
|
(Advanced breast cancer pathway) Systemic treatment G. Curigliano, IT Palliative care R. Verity, UK Oligometastatic disease A. Eniu, RO |
||
12:00 | Tumour board Breast cancer G. Curigliano, IT - O. Pagani, CH - W. Gatzemeier, IT - A. Eniu, RO - G. Pruneri, IT - R. Orecchia, IT - T. Gagliardi, UK - R. Verity, UK |
|
13:00 | Lunch with the expert |
|
14:00 | Spotlight session Fertility preservation and pregnancy in cancer patients F.A. Peccatori, IT |
|
14:45 | Women in oncology and early integration in oncology and palliative care A. Letsch, DE |
|
15:25 | Spotlight session Case presentation by a doctor and a nurse A. Letsch, DE - N. Koppotsch, DE |
|
16:20 | Spotlight session Neuroendocrine tumours C. Toumpanakis, UK |
|
18:30 | Networking Aperitif | |
19:30 | Dinner |
25 March
8:15 | Clinical session Genito-urinary cancers Chair: K. Fizazi, FR |
|
Localized prostate cancer M. Schumacher, CH Treatment of metastatic castration sensitive prostate cancer K. Fizazi, FR Castration-resistant prostate cancer K. Fizazi, FR Metastatic renal cancer: evidence-based treatment M. De Santis, DE Treatment of bladder cancer M. De Santis, DE General discussion |
||
10:45 | Coffee break | |
11:15 | Tumour board Genito-urinary cancers K. Fizazi, FR - R. Orecchia, IT - M. Schumacher, CH -M. De Santis, DE |
|
12:15 | Cancer of Unknown Primary N. Pavlidis, GR |
|
13:00 | Lunch with the expert |
|
14:00 | Clinical session Head and neck cancer Chair: Jan B. Vermorken, NL |
|
Prognostic factors and surgical approach A. Dietz, DE Radiotherapy R. Orecchia, IT Systemic therapy and radio- chemo-therapy J.B. Vermorken, NL General discussion |
||
16:00 | Tumour board Head & Neck cancer A. Dietz, DE - R. Orecchia, IT - J.B. Vermorken, NL |
|
16:30 | Spotlight session Brain tumours M. Weller, CH |
|
18:30 | Networking Aperitif |
|
19:30 | Dinner |
26 March
8:15 | Clinical session Gynaecological cancers Chair: J.B. Vermorken, BE |
|
Screening of endometrial and cervical cancer C. Sessa, CH Role of surgery in gynecological cancers I. Zapardiel, ES Systemic management of ovarian cancer J.B. Vermorken, BE Management of endometrial and cervical cancer C. Sessa, CH |
||
10:30 | Coffee break |
|
11:00 | Tumour board Gynaecological cancers (2 cases) J.B. Vermorken, DE - C. Sessa, CH - I. Zapardiel, ES |
|
11:30 | Learning Assessment Test | |
12:30 | Spotlight session Body mind medicine C. Witt, CH |
|
13:00 | Closing remarks and Awards (13:00 - 13:15) |